Affimers: a novel biotherapeutic platform for the treatment of cancer

proexus是一家新的生物技术公司，将开发一种新的人类治疗蛋白（Affimer），它将解决目前基于抗体的药物的一些缺点。抗体在治疗哮喘、关节炎和癌症等多种人类疾病方面非常成功，但它们的生产成本很高，而且由于体积大，只能通过注射给药。确认剂应该更便宜，因为它们更小，更稳定，可以局部使用（例如，作为乳霜涂抹在皮肤上或使用吸入器涂抹在肺部）。我们的第一种药物将用于治疗需要更便宜、更有效的药物的癌症。确认剂具有所有潜在的特性，可以使下一代疗法满足新药的需求

Promexus is a new biotechnology company which will be developing a novel humantherapeutic protein (the Affimer) that will address some of the shortcomings of the currentantibody based drugs. Antibodies have been very successful at treating a wide range of humandisease such as asthma, arthritis and cancer, but they are expensive to produce and because oftheir large size can only be given via an injection. Affimers should be cheaper to make andbecause they are smaller and stable, can be administered topically (for example to the skin asa cream or to the lungs using an inhaler). Our first drug will be for the treatment of cancerwhere there is a need for cheaper more effective drugs. Affimers have all the properties topotentially make the next generation of therapeutics to meet the demand of new medicines